MS-275 and Azacitidine in Treating Patients With Myelodysplastic Syndromes, Chronic Myelomonocytic Leukemia, or Acute Myeloid Leukemia
Completed
National Cancer Institute (NCI)
Phase 1
2004-11-03
MS-275 may stop the growth of cancer cells by blocking some of the enzymes needed for cell
growth. Drugs used in chemotherapy, such as azacitidine, work in different ways to stop the
growth of cancer cells, either by killing the cells or by stopping them from dividing. Giving
MS-275 together with azacitidine may kill more cancer cells. This phase I trial is studying
the side effects and best dose of MS-275 when given together with azacitidine in treating
patients with myelodysplastic syndromes, chronic myelomonocytic leukemia, or acute myeloid
leukemia.
Azacitidine and Etanercept in Treating Patients With Myelodysplastic Syndromes
Completed
National Cancer Institute (NCI)
Phase 1/Phase 2
2005-04-01
This phase I/II trial studies how well giving azacitidine together with etanercept works in
treating patients with myelodysplastic syndromes (MDS). Drugs used in chemotherapy, such as
azacitidine, works in different ways to stop the growth of cancer cells, either by killing
the cells or by stopping them from dividing. Chemoprotective drugs, such as etanercept, may
protect normal cells from the side effects of chemotherapy
Azacitidine and Etanercept in Treating Patients With Myelodysplastic Syndromes
Completed
Fred Hutchinson Cancer Research Center
Phase 1/Phase 2
2005-04-01
This phase I/II trial studies how well giving azacitidine together with etanercept works in
treating patients with myelodysplastic syndromes (MDS). Drugs used in chemotherapy, such as
azacitidine, works in different ways to stop the growth of cancer cells, either by killing
the cells or by stopping them from dividing. Chemoprotective drugs, such as etanercept, may
protect normal cells from the side effects of chemotherapy
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.
Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data.
The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free.
thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user.
Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
Alerts Available With Subscription
Alerts are available for users with active subscriptions.
